Drugs / gadobenate dimuglumine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06086704 Background | Sep 2024 → Jan 2027 expected | breast cancer | University of Wisconsin, Madison | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gadobenate dimuglumine | “gadobenate dimuglumine” NCT06086704 ↗ |
| Modality | Diagnostic / imaging agent | “FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study” NCT06086704 ↗ |
| Route | Intravenous | “gadolinium-based intravenous contrast agent” NCT06086704 ↗ |